BACE (PDF)

BACE inhibitors and their use in the treatment of Alzheimer's
Disease

BACE (beta-site of APP cleaving enzyme) is a critical
component in Alzheimer's Disease (AD), and the development of BACE
inhibitors shows great potential as a therapy for the disease.
BACE: Lead Target for Orchestrated Therapy of Alzheimer's
Disease covers virtually all aspects of BACE from initial
identification, discovery of inhibitors, and challenges in clinical
development, while providing a global understanding essential for
productive and successful drug discovery.

This book details the story of the discovery of BACE and its
role in AD and comprehensively discusses:

* The development of BACE inhibitors as therapeutics for
Alzheimer's disease

* The research that led to the identification of BACE

* New BACE inhibitors currently being clinically tested

* ADME (absorption, distribution, metabolism, excretion) and
clinical trial design--topics not addressed in current field
literature

* Cutting-edge technology such as high-throughput screening,
structure-based drug design, and QSAR in context of BACE inhibitors
and Alzheimer's drug discovery

* Other approaches to BACE inhibition based on interaction with
the precursor protein APP

By enhancing the reader's understanding of the various aspects
of the BACE drug-discovery process, this much-needed reference will
serve as a key resource for all scientists involved in Alzheimer's
research--and inspire new approaches to treatment of AD.